Coulter Partners secures Supervisory Board Directors for Pharming Group

Written by: Nola Cadman
Published on: 24 Jun 2020

Coulter Partners secures Supervisory Board Directors for Pharming Group Coulter Partners was delighted to partner recently with Pharming Group N.V. (Euronext Amsterdam: PHARM), to secure the nomination of Barbara Yanni and Mark Pykett to the Board of Supervisory Directors. An Extraordinary General Meeting of Shareholders is expected to be convened later this year for their official appointment. Until that moment, Barbara Yanni and Mark Pykett will hold an observational role within Pharming’s Board of Supervisory Directors. Pharming Group N.V. is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Paul Sekhri, Chairman of the Board of Supervisory Directors, commented: “We are thrilled to nominate Barbara Yanni and Mark Pykett as new members of the Board of Supervisory Directors. Their extensive experience and strong track record in pharmaceuticals and biotechnology in the US complements the existing expertise of our Board. Accordingly, they will further strengthen the Board’s ability to effectively oversee Pharming’s fast-growing global business activities, especially those in the increasingly important US market and I thank the team at Coulter Partners for their professional support in achieving these key nominations.” Sijmen de Vries, Chief Executive Officer, added:“I welcome Barbara Yanni and Mark Pykett to Pharming. I look forward to
working closely with them both, as we continue to implement our growth
strategy from a strong financial position with additional cash resources to
invest in the Company’s long-term prospects.”
Barbara Yanni
Barbara Yanni has over thirty-five years of experience in pharmaceuticals and
biotechnology. She currently serves as an independent director of three
public clinical-stage biopharmaceutical companies, including Trevena
(NASDAQ: TRVN), Vaccinex (NASDAQ: VCNX) and Akcea (NASDAQ:
AKCA). In the past, Barbara served as a board member of Abionyx (Paris:
ABNX) and Symic Bio, a private biotech company.
Barbara retired from Merck & Co., Inc. in 2014 after 12 years as Vice
President and Chief Licensing Officer. At Merck, Barbara and her licensing
team successfully structured and negotiated agreements to acquire rights to
over 150 compounds, programs and technologies to enhance the pipeline. In
addition, Barbara significantly increased Merck's visibility as a preferred
partner. Barbara began her Merck career as a tax lawyer and then
transitioned to finance, first as Director of Benefits Financing and
subsequently as Senior Director of Financial Evaluations and Analysis where
she evaluated the financial aspects of acquisitions, joint ventures, licenses
and other transactions.
Barbara has a JD from Stanford Law School and an AB from Wellesley
College where she studied Physics and Latin. She also holds a Masters of
Law in Taxation from New York University
Mark Pykett
Mark Pykett is Chief Scientific Officer of PTC Therapeutics (NASDAQ: PTCT).
Before joining PTC in 2018, Mark held a number of executive positions,
including president and Chief Executive Officer (CEO) of Agilis
Biotherapeutics, CEO of Navidea Biopharmaceuticals (NYSE MKT: NAVB),
and president and CEO of Alseres Pharmaceuticals (ALSE.PQ), among
others. Mark also served as a director of several public and private
companies, as well as the not-for-profit organisation, HealthBuilders, which
develops health infrastructure in central Africa.Mark received his B.A. from Amherst College, a V.M.D. and Ph.D. from the
University of Pennsylvania, and an M.B.A. from Northeastern University, and
completed postdoctoral fellowships at the University of Pennsylvania and
Harvard University.
About Pharming Group N.V.
Pharming is a specialty pharmaceutical company developing innovative
products for the safe, effective treatment of rare diseases and unmet medical
needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a
recombinant human C1 esterase inhibitor approved for the treatment of acute
Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel
and South Korea. The product is available on a named-patient basis in other
territories where it has not yet obtained marketing authorisation.
Additional information is available on the Pharming website:
About Coulter Partners
Coulter Partners is a board and senior level executive search boutique
focussed exclusively on global Life Sciences. From our offices in the UK,
Europe, North America and Asia-Pacific, we work together across boundaries
and disciplines to build outstanding leadership teams for our clients in the
pharmaceuticals, biotechnology, medical devices, health tech, diagnostics,
CRO and services sectors. Our industry leading reputation is founded on
deep sector knowledge and innovative thinking. Our strategy is built on a
unique team culture and true global reach. Our goal is to bring you the
world’s best talent.